Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02773303 · ClinicalTrials.gov registry record · NA
Neurofeedback Therapy for Children Diagnosed With Autism
A NA study, sponsored by Carrick Institute for Graduate Studies.
- Completed
- Registry status
- NA
- Development phase
- 83
- Enrollment target
NCT02773303: Completed NA study, sponsored by Carrick Institute for Graduate Studies.
NCT02773303 is a NA study that has completed, run by Carrick Institute for Graduate Studies. The registered enrollment target is 83 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02773303, a NA study, has completed, sponsored by Carrick Institute for Graduate Studies.
- COMPLETED
- Registry status
- NA
- Development phase
- 83 participants
- Enrollment target
Study Summary
This project aims: * to further explore the effectiveness of a novel sonified Neurofeedback management therapy for children diagnosed with Autism Spectrum Disorder (ASD) * to determine if balance control is different before and after therapy
Primary Outcome
Changes will be assessed between baseline (at enrollment) and after the treatment period. It will be used to investigate if Mente Autism™ therapy affect it and how much.
Interventions
- DEVICE Sham
- DEVICE Mente Autism™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-12-13 |
| Phase | NA |
What the finished NCT02773303 record still lists
NCT02773303 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT02773303 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02773303 about?
NCT02773303 is a clinical study titled "Neurofeedback Therapy for Children Diagnosed With Autism". This project aims: * to further explore the effectiveness of a novel sonified Neurofeedback management therapy for children diagnosed with Autism Spectrum Disorder (ASD) * to determine if balance control is different before and after therapy
What is the current status of trial NCT02773303?
This trial is currently completed. It is a NA study. The enrollment target is 83 participants. The study started on 2016-05. Estimated completion is 2017-12-13.
What interventions are being tested in trial NCT02773303?
The interventions under investigation include: Sham (DEVICE), Mente Autism™ (DEVICE).
Who is sponsoring clinical trial NCT02773303?
This trial is sponsored by Carrick Institute for Graduate Studies, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02773303's enrollment target sits among peer trials
83 990th of 2000 higher than 1,011 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia